SCHEMBL3336206

SCHEMBL3336206

Cc1ccc(S(=O)(=O)Nc2[c]cccc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.57
CA9 Q16790 3/20 0.57
CA1 P00915 2/20 0.57
CA12 O43570 2/20 0.57
CYP2C9 P11712 4/20 0.54
CYP2C19 P33261 4/20 0.54
LMNA P02545 3/20 0.54
ALDH1A1 P00352 2/20 0.54
USP2 O75604 1/20 0.54
POLB P06746 1/20 0.54
MAPT P10636 1/20 0.54
NOD2 Q9HC29 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
KEAP1 Q14145 1/20 0.54
NFE2L2 Q16236 1/20 0.54
GAA P10253 3/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
CA4 P22748 1/20 0.50
CA7 P43166 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1607675 0.86 KEAP1 (0.53) CA2CA9CA1CA12CYP2C9
SCHEMBL9142810 0.84 CA9 (0.42) CA2CA9CA1CA12CYP2C9
SCHEMBL1638710 0.83 CES1 (0.53) CA2CA9CA1CA12LMNA
SCHEMBL10528966 0.83 KMT2A (0.57) CA2CA9CA1CYP2C9CYP2C19
SCHEMBL6598395 0.83 KEAP1 (0.57) CA2CA1LMNAALDH1A1POLB
SCHEMBL15010431 0.80 PTGES2 (0.52) CA2CA1CYP2C9LMNAMAPT
SCHEMBL8810182 0.79 LMNA (0.63) CA2CA9CA1CA12LMNA
SCHEMBL5595031 0.79 MEN1 (0.60) CA2CA1LMNAALDH1A1POLB
SCHEMBL28676313 0.78 LMNA (0.51) CA2CA1CYP2C19LMNAALDH1A1
SCHEMBL7736129 0.77 ALDH1A1 (0.48) CYP2C9CYP2C19LMNAALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110938027-B Synthetic method of indole derivatives 河北凯诺中星科技有限公司 2022-11-25 CN claimed
CN-110938027-A Synthetic method of indole derivatives 天津大学 2020-03-31 CN claimed
US-6403633-B2 USEFUL ANTIANGIOGENIC, ANTIARTHRITIC, ANTIINFLAMMATORY, ANTIRESTENOTIC, ANTIINVASIVE, ANTIMETASTIC, ANTIOSTEOPOROTIC, ANTIRETINOPATHIC, CONTRACEPTIVE AND TUMORISTATIC TREATMENT AGENTS 3-DIMENSIONAL PHARMACEUTICALS, INC. 2002-06-11 US claimed
WO-2000030632-A1 ARYL AND HETEROARYL COMPOUNDS USEFUL AS FIBROBLAST GROWTH FACTOR ANTAGONISTS EISAI CO., LTD. (JP) 2000-06-02 WO claimed
CN-110938027-B Synthetic method of indole derivatives 河北凯诺中星科技有限公司 2022-11-25 CN disclosed
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2021-09-09 US disclosed
US-10882851-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2021-01-05 US disclosed
CN-110938027-A Synthetic method of indole derivatives 天津大学 2020-03-31 CN disclosed
US-20190152974-A1 SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS GILEAD SCIENCES, INC. 2019-05-23 US disclosed
US-10144736-B2 Substituted pteridines useful for the treatment and prevention of viral infections GILEAD SCIENCES, INC. (US) 2018-12-04 US disclosed
US-20160257673-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2016-09-08 US disclosed
EP-2791121-B1 BENZISOTHIAZOL-3(1H)-ONE-5-SULFONYL DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN INC (US) 2016-08-03 EP disclosed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed
WO-2008009076-A2 SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed
WO-2008009078-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed
WO-2000030632-A1 ARYL AND HETEROARYL COMPOUNDS USEFUL AS FIBROBLAST GROWTH FACTOR ANTAGONISTS EISAI CO., LTD. (JP) 2000-06-02 WO disclosed
US-5750552-A ANTIULCER AGENTS ARAX CO., LTD. (JP) 1998-05-12 US disclosed
EP-0736527-A1 Imadazoline derivative, possible tautomer thereof, process of manufacturing therefor, and vulnerary including such derivative or tautomer ARAX CO., LTD. (JP) 1996-10-09 EP disclosed
US-5459026-A N-phosphonoalkylindole derivatives FUJI PHOTO FILM CO., LTD. (JP) 1995-10-17 US disclosed
EP-0671660-A2 Lead-frame forming material FUJI PHOTO FILM CO., LTD. (JP) 1995-09-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR3C2, NR4A1 CA2 4225/4885CA9 3859/4885CA1 4666/4885
US-20190152974-A1 SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS HCCS, DPYD, HAVCR2 CA2 4671/4885CA9 4445/4885CA1 4862/4885
US-10144736-B2 Substituted pteridines useful for the treatment and prevention of viral infections HCCS, DPYD, HAVCR2 CA2 4671/4885CA9 4445/4885CA1 4862/4885
US-10882851-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections NR3C1, NR3C2, NR5A2 CA2 3811/4885CA9 3818/4885CA1 4516/4885
US-20160257673-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR3C2, NR5A2 CA2 3811/4885CA9 3818/4885CA1 4516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.